<SEC-DOCUMENT>0000950170-24-089281.txt : 20240801
<SEC-HEADER>0000950170-24-089281.hdr.sgml : 20240801
<ACCEPTANCE-DATETIME>20240801161010
ACCESSION NUMBER:		0000950170-24-089281
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240801
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240801
DATE AS OF CHANGE:		20240801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		241166711

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atha-20240801.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-01T14:21:29.3510+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:atha="http://athira.com/20240801" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_b2d06c3a-e327-4251-9866-da20231fc246" name="dei:AmendmentFlag" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_db7d0c16-61be-4902-a5b1-6e517046c402" name="dei:EntityCentralIndexKey" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e">0001620463</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atha-20240801.xsd"/></ix:references><ix:resources><xbrli:context id="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="agm_results"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, DC 20549</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2502eddf-a7f4-45fe-b5fc-c599dcbdcefa" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b35f11b-0fa5-46d1-89ac-69ef52400c1b" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2024</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe9c6e82-0029-4b08-bd0f-b1141ad93cd8" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"/>
    <td style="width:33.34%;"/>
    <td style="width:33.32%;"/>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_ffc801d2-1162-4ca0-beb2-49ffd7083827" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_1e08c271-abb9-4973-9f5f-0d2a90ca4a9f" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39503</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_81385d2c-9342-451b-a209-3a65fab776df" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">45-3368487</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:20.15pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ac988e7-bbce-48d1-924b-82d825c7a2d1" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18706 North Creek Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6af7dae9-9035-4f1e-b79c-ae667f0422f9" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 104</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2dc7a548-dff5-4a6c-879c-484a5fbdcf77" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bothell</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e15cb239-883e-4b5e-917f-7025bc2426e0" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73081530-cd4e-4111-9ff9-75b7f77ad503" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98011</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb586623-9a75-4498-82d9-79070e0a56b9" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">425</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_250cc1e1-e045-4022-b023-2404117cf233" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">620-8501</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.016%;"/>
    <td style="width:96.984%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_5a85c6a7-ad25-408d-bacc-22eeaab0e612" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_9e85f115-03a8-4247-a73c-815d023ba028" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_821ebaec-b0c4-4e35-a715-e92987b05d6e" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d868f799-4d94-4409-ba4c-4ffcbeebe624" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35%;"/>
    <td style="width:30%;"/>
    <td style="width:35%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7e3723dc-e38f-4102-a9b5-126ab9093197" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_a52c64c2-606d-481c-b481-0d546872a1a1" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATHA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4d6d60da-0a35-40da-af51-82ed539026e2" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;<br/>(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:75%;"/>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_815dc28a-18e7-4835-b6dd-11036ab6005c" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4aea8a6-16d2-455f-b994-a41896b84493" contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 1, 2024, Athira Pharma, Inc. (the &#8220;Company&#8221;) issued a press release reporting its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (formerly known as Twitter)(@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), Instagram account (@athirapharma) and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="atha-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Athira Pharma, Inc. press release dated August 1, 2024</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:45%;"/>
    <td style="width:5%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Athira Pharma, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;padding-right:0.042in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 1, 2024</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>atha-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img247042425_0.jpg" alt="img247042425_0.jpg" style="width:234px;height:116px;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer&#x2019;s disease targeted for September 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Phase 2/3 LIFT-AD data to be presented in an oral presentation at CTAD in October 2024</font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Phase 1 clinical trial of ATH-1105 underway for the potential treatment of amyotrophic lateral sclerosis (ALS)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">BOTHELL, Wash., August 1, 2024 &#x2013; Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2024, and provided recent pipeline and business updates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are excited to be fast approaching the topline data readout from our Phase 2/3 LIFT-AD clinical trial by the end of the third quarter, as we believe it will further support fosgonimeton's potential as a first-in-class therapy for mild-to-moderate Alzheimer&#x2019;s disease patients,&#x201d; said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. &#x201c;We were delighted to present preclinical data at the recent Alzheimer&#x2019;s Association International Conference</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">that showed fosgonimeton attenuated amyloid-&#x3b2;-induced autophagic impairments in primary cortical neurons, which may have important implications regarding the mitigation of pTau pathology and neurodegeneration observed in our preclinical models. These results suggest that fosgonimeton may have beneficial impacts on key indicators of protein pathology (pTau) and the associated neurodegeneration in Alzheimer&#x2019;s disease. Plasma biomarkers of Alzheimer&#x2019;s disease pathology, including Amyloid-&#x3b2; and pTau, will be evaluated in our LIFT-AD trial in addition to our primary endpoint combining measures of cognition and function.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Development &amp; Pipeline Programs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira&#x2019;s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system. Athira&#x2019;s drug candidates have distinct properties, which the Company believes may be applicable to a broad range of neurodegenerative diseases.</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
     </tr>
     <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton (ATH-1017)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A potentially first-in-class, once daily, subcutaneously administered drug candidate initially targeted for the potential treatment of Alzheimer&#x2019;s disease.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer&#x2019;s disease </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04488419</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira is targeting to release topline data from LIFT-AD in the third quarter of 2024 and plans to present the fuller dataset in an oral presentation at the 17</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> Annual Clinical Trials on Alzheimer&#x2019;s Disease (CTAD) taking place October 29-November 1, 2024, in Madrid, Spain. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In July 2024, Athira announced the completion of dosing for the last patient enrolled in the LIFT-AD study.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The LIFT-AD study is investigating the effects of fosgonimeton 40 mg compared with placebo in a primary analysis population of approximately 315 mild-to-moderate AD patients who are not receiving background therapy.  The primary endpoint is the Global Statistical Test (GST),</font><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> a combination of results of measures of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">cognition (ADAS-Cog11) and function (ADCS-ADL23), which Athira believes is a</font><font style="color:#222222;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> comprehensive measure of overall disease burden. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Other secondary and exploratory endpoints include changes in plasma biomarkers of neurodegeneration, protein pathology, and neuroinflammation.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Open Label Extension (OLEX) fosgonimeton trial </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04886063</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Eligible participants who complete the Company&#x2019;s LIFT-AD or ACT-AD clinical trials and elect to participate in the ongoing OLEX are able to receive up to 48 months of open-label treatment.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Notably, 85% of eligible participants who completed either study elected to enroll in OLEX.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Currently, more than 70 patients are continuing fosgonimeton treatment beyond 18 months, with nearly 50 patients continuing fosgonimeton treatment beyond 24 months, reflecting an unexpected long-term participation rate in a progressive mild-to-moderate Alzheimer&#x2019;s disease population.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira believes the OLEX will provide insights into fosgonimeton&#x2019;s long-term effects for potentially over four years of investigational treatment.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A next-generation, orally administered, small molecule drug candidate in development for the potential treatment of ALS.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira is currently conducting a first-in-human, dose escalation Phase 1 clinical trial evaluating safety, tolerability and pharmacokinetics of ATH-1105 in up to 80 healthy volunteers. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira announced the completion of the first cohort of healthy volunteers in June 2024, and the Company expects trial completion by year-end 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105&#x2019;s potential is supported by a growing body of preclinical evidence demonstrating statistically significant improvements on nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various models of ALS. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">These data have been presented at a variety of key scientific and medical meetings including the American Association of Neurology (AAN), the Alzheimer&#x2019;s Association International Congress (AAIC), the Northeast Amyotrophic Lateral Sclerosis Consortium&#174; (NEALS), and the Motor Neurone Disease Association (MNDA).  </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
     </tr>
     <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Presentations and Publications</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In July 2024, Athira presented preclinical data in poster presentations at the Alzheimer&#x2019;s Association International Conference (AAIC) 2024. One highlighted fosgonimeton&#x2019;s ability to potentially address autophagic impairment in AD, which may have important implications regarding the attenuation of pTau pathology. In the presentation titled, &#x201c;Fosgonimeton attenuates amyloid-&#x3b2;-induced autophagic impairments in primary cortical neurons,&#x201d; study authors concluded that the data &#x201c;demonstrate the ability of fosgonimeton to potentially address autophagic impairment in Alzheimer&#x2019;s disease, which may lead to the reduction of pTau pathology with treatment.&#x201d; The other presentation titled &#x201c;Neuroprotective effects of fosgonimeton and amyloid-&#x3b2;-targeting monoclonal antibo</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">d</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ies against amyloid-&#x3b2; toxicity in primary neuron culture&#x201d; highlighted research</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">that demonstrated the neuroprotective ability of fosgonimeton, alone or in combination with lecanemab, against amyloid&#x3b2;-mediated toxicity in primary neurons. Athira&#x2019;s scientific presentations can be accessed on the Athira website here: </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Medical Affairs &#x2013; Athira Pharma</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In June 2024, Athira hosted a Key Opinion Leader webinar event focused on the LIFT-AD trial endpoint of GST. The event featured presentations from Suzanne Hendrix, Ph.D., Founder and CEO of Pentara Corporation, and Anton P. Porsteinsson, M.D., Director of the University of Rochester Alzheimer&#x2019;s Disease Care, Research, and Education Program (AD-CARE). A replay of the event can be accessed </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.  </font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial Results</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash Position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Cash, cash equivalents and investments were $91.8 million as of June 30, 2024, compared to $147.4 million as of December 31, 2023. Net cash used in operations was $48.1 million for the six months ended June 30, 2024, compared to $50.5 million for the six months ended June 30, 2023.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. R&amp;D expenses were $22.2 million for the quarter ended June 30, 2024, compared to $21.6 million for the quarter ended June 30, 2023. The increase was driven primarily by an increase in ATH-1105 program costs associated with the Phase 1 clinical trial, which commenced in the second quarter of 2024. This increase was partially offset by decreases in fosgonimeton program costs, preclinical programs and other direct costs, and personnel-related expenses.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General and Administrative (G&amp;A) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">G&amp;A expenses were $5.9 million for the quarter ended June 30, 2024, compared to $10.0 million for the quarter ended June 30, 2023</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> The decrease was driven by decreases in legal costs, business development expenses, professional services expenses, and other general corporate expenses.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Net loss was $26.9 million, or $0.70 per share, for the quarter ended June 30, 2024, compared to a net loss of $29.6 million, or $0.78 per share, for the quarter ended June 30, 2023.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system. For more information, visit</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
     </tr>
     <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">w</font></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ww.athira.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. You can also follow Athira on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (formerly known as Twitter) and </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Instagram</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>This communication contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: Athira&#x2019;s drug candidates as potential treatments for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, dementia with Lewy bodies, amyotrophic lateral sclerosis and other neurodegenerative diseases; future development plans; the anticipated reporting of data; the potential learnings from preclinical studies and other nonclinical data and their ability to inform and improve future clinical development plans; expectations regarding the potential efficacy and commercial potential of Athira&#x2019;s drug candidates; and Athira&#x2019;s ability to advance its drug candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;intend,&#x201d; &#x201c;pursue,&#x201d; &#x201c;continue,&#x201d; &#x201c;suggest,&#x201d; &#x201c;potential,&#x201d; &#x201c;target,&#x201d; and similar expressions. Any forward-looking statements are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira&#x2019;s drug candidates; development of drug candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for drug candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; the anticipated timing of the topline data from the LIFT-AD trial may be delayed; whether Athira&#x2019;s trials are sufficiently powered to meet the planned endpoints; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's drug candidates with other treatments; Athira&#x2019;s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; the impact of expanded drug candidate development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira&#x2019;s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor &amp; Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie Rathbun</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie.rathbun@athira.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">206-769-9219</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands)</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
     </tr>
     <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.88%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.58%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.48%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.56%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:15.1pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">June 30,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">(unaudited)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:13.7pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:27pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Cash and cash equivalents</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">73,828</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">90,584</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:13.7pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Short-term investments</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">17,941</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">56,835</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Other short-term assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">6,562</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7,310</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:13.7pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Other long-term assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">12,922</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,516</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">111,253</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160,245</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Current liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">26,902</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">28,840</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,016</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,217</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">27,918</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">30,057</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">83,335</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">130,188</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">111,253</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160,245</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
     </tr>
     <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.129%;"></td>
    <td style="width:4.679%;"></td>
    <td style="width:18.696%;"></td>
    <td style="width:2.799%;"></td>
    <td style="width:18.696%;"></td>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Three Months Ended <br>June 30,</font></p></td>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$            22,154</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$            21,615</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;5,874</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;&#160;10,025</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:40pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:40pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;28,028</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">31,640</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;(28,028)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;(31,640)</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other income, net</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;1,169</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;2,043</font></p></td>
   </tr>
   <tr style="height:13.7pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$         (26,859)</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$         (29,597)</font></p></td>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized gain on available-for-sale securities</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;99</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;90</font></p></td>
   </tr>
   <tr style="height:13.7pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$         (26,760)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$         (29,507)</font></p></td>
   </tr>
   <tr style="height:27.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share attributable to common stockholders,<br>&#160;&#160;&#160;basic and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$             (0.70)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;$             (0.78)</font></p></td>
   </tr>
   <tr style="height:39.6pt;background-color:#cdf2ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average shares used in computing net loss per<br>&#160;&#160;&#160;share attributable to common stockholders, basic<br>&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;38,379,733</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;border-bottom:2.25pt double;padding-right:0.075in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;37,999,578</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
      <td style="width:33.333%;"></td>
     </tr>
     <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img247042425_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img247042425_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* A<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $^[13))%C5F8A54$EB
M< 5^?/QD_;*\7^)/$UW;^$=2;0O#]O(T4#VZ*9KE0<>8S,,C/4*N,9YR>:Z*
M&'G7=HF52HJ:NS]"<TG6OAO]G']KOQ+-XTT_PYXSO/[8T_4YEMH;UXU6:WE8
MA4!*@!D+$ Y&1G.>,5]R =Z5:C*A+ED.G45170ZBBBL#0**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.U<E\3O&*>"?"-Y?[
MA]J8>3;J2,M(W3ZXY/T!KK#TS7RM\>O''_"3>*VTZWDSI^FL8_9I<_.?PX'X
M'UKY_.\P67X24U\3T7K_ , ]_),O>88R--_"M7Z?\$\R:1I&9W8N['+,Q)))
M.22?4U]2?LYZ>+/X>)/CF[N9)<XZX.S_ -DKY:S7V=\+;)=/^'V@PJ-H^R(Y
M'NPW$_F:^"X1I^TQDZKZ+\V??<7U%3P<*2ZR_)'5T445^NGY$%%%% !1110
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M>2;1^IO[.WC_ /X61\(?#^K22M-?)#]DO&<Y8S1_*S'W; ;_ ($*])KXB_8
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MBKP?HOCC1I]*UW3K?4[&92K13IG&1C<IZJW/#+@CM7SS^SUX;\2?!?XR>)_
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M\$_]@V+^M=V9?!$YL+\3,7]KK_DW?Q?_ +EM_P"E,5?F37Z;?M=?\F[^+_\
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MUD8UN]0T^>UB:9B$#O&RC<0#QD^E=)16*=G=&CUT/SW_ .&"?B/_ ,_WA_\
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M*75I=:Z+DSZCJ>INT7FKM(58PJOM4$GC\R> /._^&"?B/_S_ 'A__P "Y?\
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MBB@ HHHH **** "BBB@ HHHH **** "BBD/2@#YU_P"&[OAI_=UK_P  E_\
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M\$G3]6M_$-M'^XN_W5Q@<+(!\I/U'_H/O4O[-/BO[+J=]H$S'9<+]H@YX#C
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MXBB93)=VZ_:%48"3K\LBX]G#8]L&NSS7CRBXMIG<G=7%HHHI#"BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>atha-20240801.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-01T14:21:29.5911+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://athira.com/20240801" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:atha="http://athira.com/20240801" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atha-20240801.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140183965047952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  01,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Athira Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001620463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3368487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18706 North Creek Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bothell<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $2! 5D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !$@0%9\C UK>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$G+&";UI6.G#08K;.QF9+4UBQ-C:R1]^SE9FS*V!]C1TN]/
MGT -!H5]I.?8!XKL*-V,ONV2PK 11^:@ !(>R9M4YD27F_L^>L/Y&0\0#'Z8
M T$MY2UX8F,-&YB 15B(0C<6%48RW,<SWN*"#Y^QG6$6@5KRU'&"JJQ Z&EB
M.(UM U? !&.*/GT7R"[$N?HG=NZ ."?'Y);4, SEL)IS>8<*WIX>7^9U"]<E
M-AU2_I6<XE.@C;A,?EUM[W</0M>R7A?RKI#5KI:JDDJNWR?7'WY78=];MW?_
MV/@BJ!OX=1?Z"U!+ P04    " !$@0%9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M $2! 5DEQZH1D 0  -P1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9AO<^(V$,:_BL:]Z;0S)+;,GY 4F'%(KI>YNQP7:#/33E\(6V!-;,LGR0&^
M?5>&V#0U:]Z #=;CGU:K9]<>;:1ZT3'GAFS3)--C)S8FOW%='<8\9?I2YCR#
M?U92I<S J5J[.E><1>6@-'%]SQNX*1.9,QF5O\W49"0+DXB,SQ3119HRM;OE
MB=R,'>J\_? DUK&Q/[B34<[6?,[-'_E,P9E;J40BY9D6,B.*K\9.0&]N_8$=
M4%[QI^ ;?71,[%264K[8DX=H['B6B"<\-%:"P=<KG_(DL4K \>,@ZE3WM ./
MC]_4/Y:3A\DLF>93F3R+R,1C9^B0B*]8D9@GN?G$#Q/J6[U0)KK\))O]M;V>
M0\)"&YD>!@-!*K+]-]L> G$\P#\QP#\,\$ON_8U*RCMFV&2DY(8H>S6HV8-R
MJN5H@!.9796Y4?"O@'%F<B?# H)L",LB<I\987;D(=NO-D1MY!JXB;W4#0^"
MMWM!_X1@4*POB4<[Q/?\WG^'N\!6 ?H5H%_J=4_H3>4K5^3O8*F-@B7\IXEH
MK]!K5K!Y?:-S%O*Q XFKN7KESN3GG^C ^PWAZU9\74R]#N!BE_,F.'SX\.(S
M M&K('JH2@ $44GQ,6'K)@I\_(HEFB,<_8JC?UXP9EP):1,J(I"6C7'!E<HT
M*O.H+9$&%=L 53PD]Q-?"YM* /G(TD8R7"<PL5",S&(&>Z0#FR6\1.BN*KJK
M<^BF$#S%$E"-^)9\YKLF/ES)\SPZ\+W>H(M@#2NLX3E8,$FI<JE*3^B0N8$U
M)5*1J2R %[!EU!A)7/SN'B&\K@BO49$Y#PLEC.":!"'DOT@X>2S2)5=-0+@6
M1.ZB>]WWL,A1KW96[YS8+=B6/$2PKF(EPC* "%^+9*]_T>T.AKWA%49XY/WT
M',(@BL 7=>?M@'R!Z\BWK'%)6R3I\,H;D$>I3$RFBO,7,F/J9<-V&'!="RAJ
MY3CP8B,;@7')>2$@EZF'60RMBP'%[?P]X-2>P499R$US+<7E;J6)H6'!T.H2
M07&/?X]6;>*9DJ\B"YM7&]=\#C"TNFI0W.S?H\VD-F""?XG\I+.T*%X//4HQ
MMKIJ4-SNRQ4,H.$]C8(+]/P^!E(7"(K[^A<90DQFL<PP@VL1@<)P,>Q[:&CJ
MVD!Q_WX&WS4\@\"D:9$=S$TW4N%";>T'K8L!;:D&,A$A5(-L3;Y">BO!DD8>
M7*6-QZ]K@(\;]DSQBQ#"PV%_[;M$:-2@G_VV6C6O7XM>*UGM_3YNU/\C>]"Z
M +)60%RV%?"H[\>->2$,E'*Y(M3_9?DK.=3YQH:H1<GF)U3=N9'A2X=\\"YM
MBT1RIL@K2PI.<IBOAG8.Y:Y+@(][]D*QR.;??)<N96/VM0@$BT^8K?JUX_NX
M.[^%C-QOPYAE:WZRXVT1>@SF=\%WC*FV>O\LJ[]/N5K;*/T."K95D&G.LN;%
MQ06-*M!UJXW>/^OYX'Y+8 4S+<I.;?\<TXB%JYW<!^[1L[I][_&5V4!HDO 5
M"'F75S!=M7^5L#\Q,B\?WY?2&)F6AS%GL$?M!?#_2DKS=F+?"%0O=";_ E!+
M P04    " !$@0%9GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUK
MVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-
MH<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=5
M6R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0G
MCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$
M[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,
M/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!
M6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@
M?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\
M@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T
M7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIU
MTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'
M!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=
M/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@
M/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&
MD3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?
M)=-[*CG_5U/\!%!+ P04    " !$@0%9EXJ[',     3 @  "P   %]R96QS
M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0
M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S
M##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H
M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( $2! 5D<.&7J/P$  #P"   /
M    >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2
M=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-
M;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]
MSKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE
M'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%P
MZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ
M#"PAJ748J&2W<RJGUW9PS2+W*D.:HPQH;0?AHUH+%0:P;W(@"2[)E1M27>EY
MIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " !$@0%9)!Z;HJT   #X
M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $2! 5GR,#6M[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $2!
M 5F97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 1($!627'JA&0!   W!$  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $2!
M 5F?H!OPL0(  .(,   -              "  =,,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ 1($!69>*NQS     $P(   L              ( !KP\
M %]R96QS+RYR96QS4$L! A0#%     @ 1($!61PX9>H_ 0  / (   \
M         ( !F!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $2! 5DD
M'INBK0   /@!   :              "  002  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( $2! 5EED'F2&0$  ,\#   3
M      "  >D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
' #,4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="atha-20240801.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="atha-20240801.htm">atha-20240801.htm</File>
    <File>atha-20240801.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "atha-20240801.htm": {
   "nsprefix": "atha",
   "nsuri": "http://athira.com/20240801",
   "dts": {
    "inline": {
     "local": [
      "atha-20240801.htm"
     ]
    },
    "schema": {
     "local": [
      "atha-20240801.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_81072543-1f73-42fe-9464-7c2ff6b8a96e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20240801.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_81072543-1f73-42fe-9464-7c2ff6b8a96e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20240801.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://athira.com/20240801/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-089281-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-089281-xbrl.zip
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M!%O!V&DJDV1(/L8I3\.8)^2\&7079AFVR$&2D#-LE9,SF4MU+46KZK-7 #@
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M^SE0F2C# A "9">^F9%7&U;==@F("[#(->B5!&#)*9S1;UB7"N8[1HP:JVK
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M27+CQXN@13 $9;&)=  4T,=<W\HV]R:@.I%[<F3=\6S"W"X>C).#ZK53#8\
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M3P8M_@0RI#>>L<\?XR. X 8M'P:-)^8*)5!KC#W.D;#F$ LFG2B":/J5WMV
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M%((L(=.2I0^D%, #E-;U&46=KWZ'YR^$/X(7^39[/E-M/22 'Q+W.\+V: (
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M_A]02P$"% ,4    " !$@0%9IJ!Q!/X4  "0M0  $0              @ $
M    871H82TR,#(T,#@P,2YH=&U02P$"% ,4    " !$@0%9I^ED[ T)  !M
M:0  $0              @ $M%0  871H82TR,#(T,#@P,2YX<V102P$"% ,4
M    " !$@0%9/!IK$:,B   YT $ #P              @ %I'@  871H82UE
?>#DY7S$N:'1M4$L%!@     #  , NP   #E!      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>atha-20240801_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atha-20240801.xsd" xlink:type="simple"/>
    <context id="C_81072543-1f73-42fe-9464-7c2ff6b8a96e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_b2d06c3a-e327-4251-9866-da20231fc246">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_db7d0c16-61be-4902-a5b1-6e517046c402">0001620463</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_2502eddf-a7f4-45fe-b5fc-c599dcbdcefa">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_1b35f11b-0fa5-46d1-89ac-69ef52400c1b">2024-08-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_fe9c6e82-0029-4b08-bd0f-b1141ad93cd8">Athira Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_ffc801d2-1162-4ca0-beb2-49ffd7083827">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_1e08c271-abb9-4973-9f5f-0d2a90ca4a9f">001-39503</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_81385d2c-9342-451b-a209-3a65fab776df">45-3368487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_0ac988e7-bbce-48d1-924b-82d825c7a2d1">18706 North Creek Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_6af7dae9-9035-4f1e-b79c-ae667f0422f9">Suite 104</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_2dc7a548-dff5-4a6c-879c-484a5fbdcf77">Bothell</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_e15cb239-883e-4b5e-917f-7025bc2426e0">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_73081530-cd4e-4111-9ff9-75b7f77ad503">98011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_bb586623-9a75-4498-82d9-79070e0a56b9">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_250cc1e1-e045-4022-b023-2404117cf233">620-8501</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_5a85c6a7-ad25-408d-bacc-22eeaab0e612">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_9e85f115-03a8-4247-a73c-815d023ba028">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_821ebaec-b0c4-4e35-a715-e92987b05d6e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_d868f799-4d94-4409-ba4c-4ffcbeebe624">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_7e3723dc-e38f-4102-a9b5-126ab9093197">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_a52c64c2-606d-481c-b481-0d546872a1a1">ATHA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_4d6d60da-0a35-40da-af51-82ed539026e2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_815dc28a-18e7-4835-b6dd-11036ab6005c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_81072543-1f73-42fe-9464-7c2ff6b8a96e"
      id="F_f4aea8a6-16d2-455f-b994-a41896b84493">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
